- Medicine - Atrial Fibrillation

Types	
Paroxysmal s	spontaneous termination within 7 days
Persistent r	equires cardioversion to restore sinus rhythm
Permanent s	sinus rhythm cannot be restored
Treatment	
Freq. conti	rol goal <110/min
	T Bisoprolol 2.5-5 mg
	T Digoxin 0.13-0.25 mg if heart failure
Rhythm conti	rol <i>if symtomatic</i>
Paroxysm	nal T flekainid (Tambocor) 50-100 mg x2
Persiste	ent Electrical cardioversion
	AF <48 h \rightarrow no anticoagulants needed
	AF >48 h → anticoagulants > 3 weeks before procedure (alternative: TEE)
Anticoagular	nts If CHA ₂ DS ₂ -VASc > 2
	1. NOAK, ex. dabigatran (Pradaxa)
	2. Warfarin (Waran)
	3. Long-term treatment with LMH

- Medicine - NYHA

	Mortality % (untreated) after 1 resp. 5 years			
N	AHY	Symptoms	1 y	5 y
	ı	Impaired heart function without symptoms	5	20
	II	Shortness of breath and fatigue only during strenuous exercise	10	30
	III a	Shortness of breath and fatigue during light to medium exercise	25	60
	III b	III a, and cannot walk >200m	Same as III a	
	IV	Shortness of breath and fatigue at rest. Often confined to bed.	50	80

New York Heart Association (NYHA) Functional Classification

Diagnostics modalities for heart failure (HF)

Heart ultrasound (confirms the diagnosis)

ECG (normal ECG speaks strongly against HF)

Plain film X-ray (heart/lung, to exclude other conditions)

NT-proBNP (if low + ok ECG, rules out HF w. high certainty)

Lab tests (Hb, Na, K, Crea., PK, B-glucose, TSH, CRP, iron)

- Medicine -

Heart Failure Treatment

III + IV Advanced treatment/palliative care.

*If not tolerated → Angiotensin II receptor antagonist, EF = Ejection Fraction

Drug class	Example	Start (mg)	Target (mg)
ACE-Inhibitor	Enalapril	2.5 x 2	10-20 x 2
Diuretic	Furix	20 - 40	40 - 240
Beta-blocker	Bisoprolol	1.25 x 1	10 x 1
Aldosterone antagonist	Spironolakton	25 x 1	25-50 x 1
Angiotensin II antagonist	Candesartan	4-8 x 1	32 x 1

Acute heart failure (left ventricle)

Heart position

Oxygen (target SaO2 >90%) or CPAP if severe lung oedema

Furosemid (10 mg/ml 2-4 ml i.v.)

Nitroglycerin i.v. (0.25-0.5 mg) or

spray (0.4 mg) sublingually if systolic BP >100

- Medicine - CHA2DS2VAS

С	Cardiac - Heart failure	1
Н	Hypertension	1
Α	Age ≥ 75 years	2
D	Diabetes	1
S	Stroke / TIA / Embolism	2
V	Vascular Atherosclerotic disease	1
Α	Age 65-74	1
S	Sex - Female*	1

^{*}No indication for antithrombotic treatment if only risk factor

AF and score ≥2 → Antithrombotic treatment *IF* low-medium risk of bleeding (HAS-BLED <3)

See local guidelines for specific antithrombotic drugs

Example of initial Warfarin treatment, 2.5mgx1 p.o.

Day 1: 2-4 | Day 2: 2-3 | Day 3: 1-4 (dep. on INR)